EQT Life Sciences, formerly known as LSP, one of Europe’s largest life sciences investors, has announced that its LSP Health Economics Fund has exited Vivasure Medical Limited, a Galway-based medical device company, following its acquisition by Haemonetics Corporation, a global medical technology company.

Vivasure develops next-generation technologies for percutaneous vessel closure, with its flagship PerQseal Elite system designed to seal large arterial and venous access sites from within the vessel. The system uses a fully bioabsorbable, sutureless patch and is intended for use in structural heart and endovascular procedures.

In 2025, Vivasure submitted a Premarket Approval (PMA) application to the US Food and Drug Administration for PerQseal Elite and also received CE Mark approval in Europe for both arterial and venous indications.

EQT Life Sciences first invested in Vivasure in 2016, leading the company’s Series C financing round through the LSP Health Economics Fund. Between 2016 and 2025, EQT was represented on Vivasure’s board by Anne Portwich, Partner at EQT Life Sciences, providing active strategic guidance as the company advanced its technology through clinical development and toward regulatory approval.

Under the terms of the transaction, Haemonetics will acquire Vivasure for an upfront cash consideration of EUR 100 million, with the potential for up to an additional EUR 85 million in contingent payments linked to sales growth and the achievement of specific milestones. The LSP Health Economics Fund will receive proceeds in line with its minority shareholding.

“It has been a great honour to serve on the board of Vivasure,” said Anne Portwich, Partner at EQT Life Sciences. “Supporting companies that improve treatment quality and expand patient access is central to our health economics strategy. This successful exit also highlights the vital role venture capital plays in translating medical innovation into clinical practice.”

Andrew Glass, Chief Executive Officer of Vivasure Medical, said the acquisition marks a major milestone for the company. “We are extremely proud of the progress made in advancing vessel closure technology and grateful to the clinicians, employees, investors, and partners who supported our mission. Becoming part of Haemonetics provides the scale and resources needed to accelerate global access to PerQseal Elite.”

Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics, said the acquisition strengthens the company’s position in advanced closure technologies. “Vivasure adds clinically differentiated technology to our closure portfolio and enhances our presence in the growing large-bore closure market for structural heart and endovascular procedures.”

EQT Life Sciences was formed in 2022 following the integration of LSP into the EQT platform. As LSP, the firm raised more than EUR 3.0 billion and supported over 150 life sciences and healthcare companies over more than three decades. EQT Life Sciences focuses on backing innovations with the potential to deliver meaningful improvements in patient care.

Founded in Galway, Ireland, Vivasure Medical specializes in polymer-based implants and delivery systems for minimally invasive vessel closure across cardiology, interventional radiology, and vascular surgery.

Haemonetics is a global medical technology company focused on improving the quality, effectiveness, and efficiency of healthcare through hospital technologies, plasma collection systems, and blood management solutions.